Arcturus Therapeutics (ARCT)

What Could Go Wrong

1. 01Clinical trial failure risk - Phase 2/3 programs have 30-40% historical success rates in rare diseases, with binary outcomes that could render platform value negligible
2. 02mRNA delivery technology commoditization as Moderna, BioNTech, and other well-capitalized competitors advance lipid nanoparticle platforms with superior resources
3. 03Regulatory pathway uncertainty for rare disease accelerated approvals, particularly as FDA scrutiny on surrogate endpoints intensifies post-2023
4. 04Reimbursement challenges for ultra-rare disease treatments requiring $500K-$2M+ annual pricing to achieve commercial viability
5. 05Moderna and BioNTech expanding into rare disease mRNA therapeutics with significantly larger cash reserves ($10B+ vs $150M) and established manufacturing infrastructure
6. 06Gene therapy competitors (BioMarin, Ultragenyx's own programs) offering potential one-time curative treatments versus chronic mRNA dosing for conditions like OTC deficiency
7. 07Acquisition of Translate Bio by Sanofi and Arbutus by Roivant consolidating mRNA delivery IP and creating well-funded competitive threats
8. 08Cash runway of 12-18 months (estimated) requires near-term financing, likely dilutive equity raise given current 0.9x P/B valuation and limited debt capacity

ARCT Chart

My Notes

• growth/speculative - Attracts high-risk-tolerance biotech specialists, hedge funds with event-driven strategies around clinical catalysts…
• Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (8-10+ years for most…
• Watch on earnings: ARCT-810 Phase 2/3 trial enrollment completion and interim data readout timing for OTC deficiency, Cash and marketable securities balance versus quarterly burn rate to assess financing urgency, Collaboration revenue from CSL Seqirus and Ultragenyx partnerships as indicator of platform validation.